Research programme: cataract therapies - Senju

Drug Profile

Research programme: cataract therapies - Senju

Alternative Names: Anti-cataracts - Senju; Calpain inhibitors research programme - Senju; Cataract therapies research programme - Senju; SJA 6017; SNJ 1757

Latest Information Update: 05 Feb 2008

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Class Glycoproteins
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cataracts

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Cataracts in Japan (Ophthalmic)
  • 08 Jun 2004 A preclinical study has been added to the Eye Disorders pharmacodynamics section
  • 19 Mar 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top